HER2 Clinical Trials in Shanghai, Shanghai Municipality
32 recruitingShanghai, Shanghai Municipality, China
Showing 1–20 of 32 trials
Recruiting
Phase 3
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC2,400 enrolled268 locationsNCT06966700
Recruiting
Phase 2
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Advanced Solid TumorsHER2 Mutation
Bayer111 enrolled54 locationsNCT06760819
Recruiting
Phase 3
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
HER2-positive Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.544 enrolled78 locationsNCT07043725
Recruiting
Phase 2
Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer
Metastatic Breast Cancer ( HER2 Negative)
Fudan University45 enrolled2 locationsNCT07471776
Recruiting
Phase 1Phase 2
A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
Metastatic Breast CancerLocally Advanced Breast CancerBreast Cancer Stage IV+1 more
Forward Pharmaceuticals Co., Ltd.99 enrolled22 locationsNCT06064812
Recruiting
Phase 2
ctDNA-guided Treatment Decision-making
Metastatic Breast Cancer ( HER2 Negative)ctDNA
Fudan University122 enrolled1 locationNCT07394218
Recruiting
Phase 3
A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer
Early-stage or Locally Advanced HER2-positive Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.740 enrolled2 locationsNCT07196774
Recruiting
Phase 1Phase 2
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
HER2-positive Advanced Solid Tumor
DualityBio Inc.796 enrolled102 locationsNCT05150691
Recruiting
Phase 3
A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy
HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.1,450 enrolled2 locationsNCT06830889
Recruiting
Phase 3
A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)
HER2-positive Breast Cancer
Fudan University2,306 enrolled1 locationNCT06992882
Recruiting
Phase 2
A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients
HER2-low Hormone Receptor Positive Breast Cancer
Shanghai Henlius Biotech50 enrolled1 locationNCT06832202
Recruiting
Phase 3
A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
Jiangsu HengRui Medicine Co., Ltd.1,600 enrolled2 locationsNCT06126640
Recruiting
Phase 2
Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab
HER2-negative Breast CancerBRCA-Mutated Breast Carcinoma
Fudan University130 enrolled1 locationNCT06516289
Recruiting
Not Applicable
Pilot Study of Neoadjuvant Chemotherapy Combined With Immunotherapy and Multimodal Thermal Therapy for HER2-negative Breast Cancer
Breast Cancer FemaleHER2-negative Breast Cancer
Fudan University14 enrolled1 locationNCT06636591
Recruiting
Phase 2
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
Breast CancerBreast NeoplasmHER2-negative Breast Cancer+2 more
Fudan University620 enrolled1 locationNCT05594095
Recruiting
Phase 1Phase 2
A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer
Advanced Solid TumorHR+/HER2- Breast Cancer
Beta Pharma (Suzhou) Co., Ltd.224 enrolled1 locationNCT04282031
Recruiting
Phase 3
Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer
Advanced Breast CancerHR+/HER2- Breast Cancer
Fudan University184 enrolled1 locationNCT06447623
Recruiting
Phase 3
DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer
HER2-positive Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.442 enrolled1 locationNCT06313086
Recruiting
Phase 3
EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer
HER2 Positive Early Breast Cancer
Fudan University1,406 enrolled1 locationNCT05883852
Recruiting
Not Applicable
Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer
HER2-positive Breast Cancer
Fudan University94 enrolled1 locationNCT04281641